MARKET

MRKR

MRKR

Marker Therapeut
NASDAQ
4.140
+0.040
+0.97%
After Hours: 4.140 +0.05 +1.22% 16:00 04/19 EDT
OPEN
4.260
PREV CLOSE
4.100
HIGH
4.260
LOW
4.050
VOLUME
14.96K
TURNOVER
0
52 WEEK HIGH
9.68
52 WEEK LOW
0.7600
MARKET CAP
36.86M
P/E (TTM)
-4.4278
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MRKR last week (0408-0412)?
Weekly Report · 6d ago
Marker Therapeutics’ MT-601 Shows Promising Results
TipRanks · 04/08 16:07
Weekly Report: what happened at MRKR last week (0401-0405)?
Weekly Report · 04/08 11:10
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Barchart · 04/08 06:00
Weekly Report: what happened at MRKR last week (0325-0329)?
Weekly Report · 04/01 11:08
Marker Therapeutics Advances in Immuno-Oncology
TipRanks · 03/26 17:07
Marker Therapeutics GAAP EPS of -$1.59, revenue of $3.31M
Marker Therapeutics reports FY GAAP EPS of -$1.59, revenue of $3.31M. At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The company expects to fund its operating expenses through the end of 2024.
Seeking Alpha · 03/26 05:13
Marker Therapeutics Reports 2023 Net Loss Of $(8.2)M Vs. Net Loss Of $(29.9)M Last Year
At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The company believes it will fund its operating expenses into the fourth quarter of 2025. Marker reported a net loss of $8.2 million for the year ended December 31.
Benzinga · 03/25 21:56
More
About MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Webull offers Marker Therapeutics Inc stock information, including NASDAQ: MRKR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRKR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRKR stock methods without spending real money on the virtual paper trading platform.